eventSeriesName is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Informa

Component List

Component Guide

In person - day 1

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sustainability Strategies in the Life Sciences Industry

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

SPEAKERS
Elon Musk
Acme corp.
Bill Gates
Acme corp.
Elon Musk
Acme corp.
Bill Gates
Acme corp.
DISCUSSION POINTS
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
TALK SPONSOR

2nd Nov  10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sourcing Responsibly – Putting ESG Principles Into Practice
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Keynote Sustainability
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Why Biopharma CDMO Companies Must Transition with Long-Term Sustainability in Mind
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Indena's Commitment to Sustainability: From Responsible Supply Chain Management to Smart Use of Energy, we aim to Protect Nature, People, and Business
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.
In person - day 1

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sustainability Strategies in the Life Sciences Industry

Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

SPEAKERS
Elon Musk
Acme corp.
Bill Gates
Acme corp.
DISCUSSION POINTS

Lorem ipsum dolor sit amet

  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
  • Lorem ipsum dolor sit amet
TALK SPONSOR

2nd Nov  10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Sourcing Responsibly – Putting ESG Principles Into Practice
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Keynote Sustainability
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Why Biopharma CDMO Companies Must Transition with Long-Term Sustainability in Mind
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.

2nd Nov 10:00 - 10:30 (CET)

Stand 30J20, Hall 3.1- Keynote
Indena's Commitment to Sustainability: From Responsible Supply Chain Management to Smart Use of Energy, we aim to Protect Nature, People, and Business
Believe it or not, about 20 years' worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can't get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline.